New Drugs for Obesity, Is the Excitement Affordable?
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/10/01
-
Journal
-
Indian UGC (journal)
-
Refrences2
-
Ian Duncan Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, California, USA.Diabetes Technology Society, Santa Barbara, California, USA.
-
David Kerr Diabetes Technology Society, Santa Barbara, California, USA.
-
Rajesh Aggarwal Twenty 30 Health, Erdenheim, Pennsylvania, USA.
-
Nhan Huynh Santa Barbara Actuaries, Inc., Santa Barbara, California, USA.
Cite
Duncan, Ian, et al. “New Drugs for Obesity, Is the Excitement Affordable?”. Population Health Management, vol. 26, no. 5, 2023, pp. 356-7, https://doi.org/10.1089/pop.2023.0086.
Duncan, I., Kerr, D., Aggarwal, R., & Huynh, N. (2023). New Drugs for Obesity, Is the Excitement Affordable?. Population Health Management, 26(5), 356-357. https://doi.org/10.1089/pop.2023.0086
Duncan I, Kerr D, Aggarwal R, Huynh N. New Drugs for Obesity, Is the Excitement Affordable?. Population Health Management. 2023;26(5):356-7.
Journal Categories
Medicine
Medicine (General)
Medicine
Medicine (General)
Medical technology
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension | Diabetes, Obesity and Metabolism |
| 170 | 2022 |
Semaglutide for the treatment of overweight and obesity: A review | Diabetes, Obesity and Metabolism |
| 34 | 2022 |